Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 5/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3073460 | 0.82 | PIK3CD (0.40) | CHEK1JAK3PIK3CDJAK2PRKCQ | |
| SCHEMBL3075706 | 0.78 | CHEK1 (0.59) | CHEK1JAK3PIK3CDJAK2KCNH2 | |
| SCHEMBL3079109 | 0.74 | CHEK1 (0.53) | CHEK1JAK3PIK3CDJAK2KCNH2 | |
| SCHEMBL4355022 | 0.69 | CHEK1 (0.50) | CHEK1JAK3PIK3CDJAK2PRKCQ | |
| SCHEMBL4357649 | 0.69 | CHEK1 (0.47) | CHEK1PIK3CDKCNH2 | |
| SCHEMBL38664072 | 0.69 | USP30 (0.46) | JAK3PIK3CDUSP30 | |
| SCHEMBL4342847 | 0.67 | CHEK1 (0.47) | CHEK1PIK3CDKCNH2PIK3CA | |
| SCHEMBL4347474 | 0.66 | CHEK1 (0.68) | CHEK1JAK3JAK2KCNH2 | |
| SCHEMBL16321232 | 0.65 | TRPA1 (0.49) | AR | |
| SCHEMBL4350214 | 0.65 | JAK3 (0.44) | CHEK1JAK3PIK3CDJAK2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | CHEK1 1/4885JAK3 2752/4885PIK3CD 218/4885 |
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | CHEK1, CHEK2, MCL1 | CHEK1 1/4885JAK3 562/4885PIK3CD 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.